Current Dyslipidemia Management: What do the 2021 CCS Guidelines Say?

Welcome to the podcast series CAN-R³: Canadian Initiative to Reduce Residual Risk – Game Changers in Dyslipidemia Management. In this series, Canadian experts discuss the importance and challenges of reducing LDL-C in patients with established ASCVD, recommendations from the 2021 Canadian Cardiovascular Society Guidelines, and evidence around statins efficacy and adherence in different patient populations. Visit iMedicus.ca/Dyslipidemia to watch the Section 1 accredited webinars.

 

In this first episode, Dr. Judy Luu and Dr. Shaun Goodman exchange on the different contributors to residual risk, the role of LDL-C in atherosclerosis, the importance of reducing LDL-C as low as possible, identifying patients who benefit the most from intensification therapy beyond statins, and the shift to LDL-C thresholds as opposed to treatment targets.